About Us

Fresenius Kabi at a glance

Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, we offer products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems. In the field of biosimilars, we develop products with a focus on oncology and autoimmune diseases.

About us

Fresenius Kabi employs about 35,000 people worldwide.

With our corporate philosophy of "caring for life", we are committed​ to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.

In 2016 the company reported sales of €6 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.

Key Figures

€ in millions 2016 2015 Change
Sales 6,007 5,950 1%
EBITDA1 1,479 1,446 2%
EBIT1 1,224 1,189 3%
Net Income2 716 669 7%
Employees 34,917 33,195 5%

1 2015 before special items
2 Net income attributable to shareholders of Fresenius Kabi AG; 2015 before special items